Evidence map›Paper›PMID 40610725›Full record

ArticleNPJ precision oncology2025

Prevalence and biological impact of clinically relevant gene fusions in head and neck cancers.

Emily L Hoskins, Raven Vella, Julie W Reeser, Michele R Wing, Eric Samorodnitsky, Altan Turkoglu, Leah Stein, Elizabeth Breuning, Zachary A Risch, Wilnelly M Hernandez-Sanchez and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Fibroblast growth factor receptor signaling in head and neck tumors: molecular pathogenesis and potential therapeutic targets.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Emily L HoskinsComprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA.
Raven VellaComprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA.
Julie W ReeserComprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA.
Michele R WingComprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA.
Eric SamorodnitskyComprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA.
Altan TurkogluComprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA.
Leah SteinComprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA.
Elizabeth BreuningThe Bioinformatics Program, Loyola University Chicago, Chicago, IL, USA.
Zachary A RischComprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA.
Wilnelly M Hernandez-SanchezCaris Life Sciences, Irving, TX, USA.
Lianbo YuDepartment of Biomedical Informatics, The Ohio State University, Columbus, OH, USA.
Michelle ChurchmanAster Insights, Tampa, FL, USA.
Nancy SingleComprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA.
Jad ChahoudDepartment of Genitourinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Antonio JimenoDepartment of Surgery, University of Colorado School of Medicine, Aurora, Colorado, USA.
Michael J CavnarDivision of Surgical Oncology, Department of Surgery, University of Kentucky Markey Comprehensive Cancer Center, Lexington, KY, USA.
Matthew ReilleyDivision of Hematology and Oncology, Department of Medicine, University of Virginia Health System, Charlottesville, VA, USA.
Courtney ScaifeDepartment of Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA.
Kenneth G NeppleDepartment of Urology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
Minh PhanDepartment of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Ok, USA.
Bryan SchneiderIndiana University School of Medicine, Indianapolis, IN, USA.
Stephen EdgeRoswell Park Cancer Institute, University at Buffalo, Buffalo, NY, USA.
Bodour SalhiaDepartment of Neurosurgery Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Aliza LeiserRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Trisha M Wise-DraperDivision of Hematology and Oncology, University of Cincinnati, Cincinnati, OH, USA.
Michael K WendtDivision of Hematology and Oncology, Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.
Sameek RoychowdhuryComprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA. Sameek.roychowdhury@osumc.edu.

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Jennifer F Rogers · 2013 to 2026
$38.3M
Liquid Biopsy for Rapid Detection and Real Time Monitoring of FGFR-altered CancersUH2CA262220 · NCI · OHIO STATE UNIVERSITY · PI ROYCHOWDHURY, SAMEEK · 2021 to 2022
$357k
NCI NIH HHS P30 CA016058NCI NIH HHS P30 CA177558NCI NIH HHS UH2 CA262220NCI NIH HHS UH2CA262220
6 · The paper itself

Abstract

Head and neck cancer (HNC) is the seventh most common cancer worldwide. Currently-approved systemic therapies include chemotherapy, anti-EGFR antibodies, and PD-1 immunotherapy, with few genomic-based targeted therapies. Gene fusions involving cancer-driving kinase genes such as FGFR, NTRK, and ALK are clinically targetable in other solid tumors; however, there is limited knowledge about their prevalence in HNC. Here, we describe the genomic landscape and the biological impact of oncogenic fusions in a combined dataset of over 13,000 HNC tumors (excluding salivary gland tumors). We identified 66 cases (2.8%) harboring oncogenic fusions, including previously-reported FGFR3 fusions (n = 19) and gain-of-function EGFR fusions (n = 6). Fusion-positive HNC had significantly higher gene expression and higher prevalence of human papillomavirus than fusion-negative HNC (p < 0.001). Tumors with FGFR alterations were associated with enriched cell proliferation and higher abundance of NK cells and CD8+ T cells compared to wildtype. Our results provide expanded therapeutic opportunities for patients with HNCs.

Identifiers

PMID40610725
PMCPMC12229568

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.